The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
Abstract
BACKGROUND: Fibromyalgia syndrome (FMS) is a clinically well-defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of life (QOL). Drug therapy focuses on reducing key symptoms and improving quality of life. OBJECTIVES: To assess the benefits and harms of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo for treating FMS symptoms in adults. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library 2012, Issue 9), MEDLINE (1966 to September 2012), EMBASE (1980 to September 2012), www.clinicalstudyresults.org (U.S.-marketed pharmaceuticals) (to September 2012) and www.clinicaltrials.gov (to September 2012) for published and ongoing trials and examined the reference lists of reviewed articles. SELECTION CRITERIA: We selected randomized, controlled trials of any formulation of SNRIs against placebo for the treatment of FMS in adults. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted the data from the included studies, and assessed the risks of bias of the studies. Discrepancies were resolved by discussion. MAIN RESULTS: Ten studies were included with a total of 6038 participants. Five studies investigated duloxetine against placebo, and five investigated milnacipran against placebo. A total of 3611 participants were included into duloxetine or milnacipran groups and 2427 participants into placebo groups. The studies had a low risk of bias in general. Duloxetine and milnacipran had a small incremental effect over placebo in reducing pain (standardized mean difference (SMD) -0.23; 95% confidence interval (CI) -0.29 to -0.18; 6.1% relative improvement). One-hundred and ninety-two participants per 1000 on placebo reported an at least 50% pain reduction compared to 280 per 1000 on SNRIs (Risk ratio (RR) 1.49, 95% CI 1.35 to 1.64; number needed to treat to benefit (NNTB) 11, 95% CI 9 to 15). Duloxetine and milnacipran did not reduce fatigue substantially (SMD -0.14; 95% CI -0.19 to -0.08; 2.5% relative improvement; NNTB 17, 95% CI 12 to 29), and did not improve QOL substantially (SMD -0.20; 95% CI -0.25 to -0.14; 4.6% relative improvement; NNTB 12, 95% CI 9 to 17) compared to placebo. There were no statistically significant differences between either duloxetine or milnacipran and placebo in reducing sleep problems (SMD -0.07; 95% CI -0.16 to 0.03; 2.5% relative improvement). One-hundred and seven participants per 1000 on placebo dropped out due to adverse events compared to 196 per 1000 on SNRIs. The dropout rate due to adverse events in the duloxetine and milnacipran groups was statistically significantly higher than in placebo groups (RR 1.83, 95% CI 1.53 to 2.18; number needed to treat to harm (NNTH) 11, 95% CI 9 to 13). There was no statistically significant difference in serious adverse events between either duloxetine or milnacipran and placebo (RR 0.78, 95% CI 0.55 to 1.12). AUTHORS' CONCLUSIONS: The SNRIs duloxetine and milnacipran provided a small incremental benefit over placebo in reducing pain. The superiority of duloxetine and milnacipran over placebo in reducing fatigue and limitations of QOL was not substantial. Duloxetine and milnacipran were not superior to placebo in reducing sleep problems. The dropout rates due to adverse events were higher for duloxetine and milnacipran than for placebo. The most frequently reported symptoms leading to stopping medication were nausea, dry mouth, constipation, headache, somnolence/dizziness and insomnia. Rare complications of both drugs may include suicidality, liver damage, abnormal bleeding, elevated blood pressure and urinary hesitation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls
Yunus, M., Masi, A. T., Calabro, J. J., Miller, K. A., & Feigenbaum, S. L. (1981) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(81)90096-2 · Cited by 910
Prevalence of Fibromyalgia: A Survey in Five European Countries
Branco, J. C., Bannwarth, B., Failde, I., Abello Carbonell, J., Blotman, F., Spaeth, M., Saraiva, F., Nacci, F., Thomas, E., Caubère, J.-P., et al. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.12.003 · Cited by 685
Dworkin, R. H., Turk, D. C., McDermott, M. P., Peirce-Sandner, S., Burke, L. B., Cowan, P., Farrar, J. T., Hertz, S., Raja, S. N., Rappaport, B. A., et al. (2009) · Pain · doi:10.1016/j.pain.2009.08.019 · Cited by 654
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Cited by
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566
Self-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment
Sarzi-Puttini, P., Giorgi, V., Marotto, D., & Atzeni, F. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00506-w · Cited by 793
Häuser, W., Ablin, J., Fitzcharles, M.-A., Littlejohn, G., Luciano, J. V., Usui, C., & Walitt, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.22 · Cited by 505
Self-citationDrossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
Brandow, A. M., Carroll, C. P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R. W., Kutlar, A., Seisa, M., Stinson, J., Strouse, J. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001851 · Cited by 456
Hodges, P. W., & Smeets, R. J. (2015) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000098 · Cited by 351
Management of functional somatic syndromes and bodily distress
Henningsen, P., Zipfel, S., Sattel, H., & Creed, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000484413 · Cited by 335
Resistance exercise training for fibromyalgia
Busch, A. J., Webber, S. C., Richards, R. S., Bidonde, J., Schachter, C. L., Schafer, L. A., Danyliw, A., Sawant, A., Dal Bello-Haas, V., Rader, T., et al. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010884 · Cited by 333
Bair, M. J., & Krebs, E. E. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202003030 · Cited by 298
Fibromyalgia Pathogenesis and Treatment Options Update
Chinn, S., Caldwell, W., & Gritsenko, K. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0556-x · Cited by 296
Cognitive behavioural therapies for fibromyalgia
Bernardy, K., Klose, P., Busch, A. J., Choy, E. H., & Häuser, W. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009796.pub2 · Cited by 272
Self-citationReview of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
“Although patients may initially experience symptom relief with good tolerance, the majority will ultimately discontinue therapy because of inadequate response or unacceptable side effects [17,21,22].”
BackgroundInfluentialSelf-citationResting state connectivity correlates with drug and placebo response in fibromyalgia patients
Schmidt-Wilcke, T., Ichesco, E., Hampson, J. P., Kairys, A., Peltier, S., Harte, S., Clauw, D. J., & Harris, R. E. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.09.007 · Cited by 122
Current and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“A meta-analysis reviewing five different studies regarding duloxetine and five different studies regarding and milnacipran showed that these drugs had positive effects on pain and patient-perceived clinical improvement [12].”
Juvenile fibromyalgia: current status of research and future developments
Kashikar-Zuck, S., & Ting, T. V. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.177 · Cited by 106
Walitt, B., Katz, R. S., Bergman, M. J., & Wolfe, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157235 · Cited by 97
Self-citationPharmacotherapy for postural tachycardia syndrome
Miller, A. J., & Raj, S. R. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.04.008 · Cited by 91
Unravelling Fibromyalgia—Steps toward Individualized Management
Häuser, W., Perrot, S., Clauw, D. J., & Fitzcharles, M.-A. (2018) · The Journal of Pain · doi:10.1016/j.jpain.2017.08.009 · Cited by 72
Self-citationLuciano, J. V., D’Amico, F., Cerdà-Lafont, M., Peñarrubia-María, M. T., Knapp, M., Cuesta-Vargas, A. I., Serrano-Blanco, A., & García-Campayo, J. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0451-y · Cited by 48
Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis
Kudlow, P. A., Rosenblat, J. D., Weissman, C. R., Cha, D. S., Kakar, R., McIntyre, R. S., & Sharma, V. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.030 · Cited by 40
Management of widespread pain and fibromyalgia
Whibley, D., Dean, L. E., & Basu, N. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0056-5 · Cited by 23
Metadata
- Authors
- Häuser, W., Urrútia, G., Tort, S., Üçeyler, N., & Walitt, B.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-01-31
- Issue
- 1
- Pages
- CD010292-CD010292
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2114702376
- Cited by
- 166
- References
- 23
- FWCI
- 15.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.